Bradley Katherine, Feldman Elizabeth A, Schrader Joshua, Meola Gregory, Miller Christopher D, Darko William, Seabury Robert
Upstate University Hospital, Department of Pharmacy, 750 East Adams Street, Syracuse, NY, USA.
Upstate University Hospital, Department of Pharmacy, 750 East Adams Street, Syracuse, NY, USA.
Am J Emerg Med. 2025 Jan;87:51-56. doi: 10.1016/j.ajem.2024.10.044. Epub 2024 Oct 28.
This study sought to assess the cardiorespiratory safety of parenteral olanzapine and benzodiazepine combination treatment compared to parenteral droperidol or haloperidol and benzodiazepine combination treatment.
This was a retrospective chart review conducted in adult emergency department patients who received intramuscular (IM) or intravenous (IV) droperidol, haloperidol, or olanzapine within one hour of IM or IV benzodiazepine. Patients were stratified into groups based on whether they received either olanzapine in combination with a benzodiazepine (n = 48) or droperidol or haloperidol in combination with a benzodiazepine (n = 48).
Patients in each group had a decrease in their systolic blood pressure (SBP) after IM/IV olanzapine and IM/IV droperidol or haloperidol when used in combination with an IM/IV benzodiazepine ((Olanzapine + benzodiazepine (mmHg), median (IQR): Pre-SBP: 132 (117-151) vs. Post-SBP: 117 (99-131), p < 0.01) (Droperidol or haloperidol + benzodiazepine (mmHg), median (IQR): Pre-SBP: 138 (122-149) vs. Post-SBP: 106 (98-127), p < 0.01)). Both groups had similar percent SBP decreases post-combination treatment (Olanzapine + benzodiazepine (15.6 %) vs. Droperidol or haloperidol + benzodiazepine (15.2 %); p = 0.55). We did not observe any statistically significant between group differences for hypotension (Olanzapine + benzodiazepine: 1/48, 2.1 % vs. Droperidol or haloperidol + benzodiazepine: 3/48, 6.3 %; p = 0.62)), escalation in oxygen requirements (Olanzapine + benzodiazepine: 7/48, 14.6 %) vs. Droperidol or haloperidol + benzodiazepine: 5/48, 10.4 %; p = 0.76)), or intubation due to cardiorespiratory depression (Olanzapine + benzodiazepine: 0/0, 0 % vs. Droperidol or haloperidol + benzodiazepine: 0/0, 0 %; p = 1.00)).
This study found decreases in SBP after administering parenteral olanzapine and parenteral droperidol or haloperidol in combination with a parenteral benzodiazepine. The percent change in SBP and the frequency of hypotensive episodes post-combination treatment were not different between groups. There were also no differences between groups in need of increased oxygen requirements post-combination treatment or need for intubation due to cardiorespiratory depression. This study suggests parenteral olanzapine in combination with a parenteral benzodiazepine may have comparable cardiorespiratory safety versus parenteral droperidol or haloperidol in combination with a parenteral benzodiazepine when treating agitation in the adult ED.
本研究旨在评估与肌内注射或静脉注射氟哌利多或氟哌啶醇联合苯二氮䓬治疗相比,肌内注射或静脉注射奥氮平联合苯二氮䓬治疗的心肺安全性。
这是一项回顾性病历审查,研究对象为成年急诊科患者,这些患者在肌内注射或静脉注射苯二氮䓬一小时内接受了肌内注射(IM)或静脉注射(IV)氟哌利多、氟哌啶醇或奥氮平。根据患者是否接受奥氮平联合苯二氮䓬(n = 48)或氟哌利多或氟哌啶醇联合苯二氮䓬(n = 48)进行分组。
每组患者在肌内注射/静脉注射奥氮平以及肌内注射/静脉注射氟哌利多或氟哌啶醇联合肌内注射/静脉注射苯二氮䓬后,收缩压(SBP)均有所下降((奥氮平 + 苯二氮䓬(mmHg),中位数(IQR):注射前SBP:132(117 - 151),注射后SBP:117(99 - 131),p < 0.01)(氟哌利多或氟哌啶醇 + 苯二氮䓬(mmHg),中位数(IQR):注射前SBP:138(122 - 149),注射后SBP:106(98 - 127),p < 0.01))。联合治疗后两组SBP下降百分比相似(奥氮平 + 苯二氮䓬(15.6%)对氟哌利多或氟哌啶醇 + 苯二氮䓬(15.2%);p = 0.55)。我们未观察到两组间低血压(奥氮平 + 苯二氮䓬:1/48,2.1%对氟哌利多或氟哌啶醇 + 苯二氮䓬:3/48,6.3%;p = 0.62)、吸氧需求增加(奥氮平 + 苯二氮䓬:7/48,14.6%对氟哌利多或氟哌啶醇 + 苯二氮䓬:5/48,10.4%;p = 0.76)或因心肺抑制导致插管(奥氮平 + 苯二氮䓬:0/0,0%对氟哌利多或氟哌啶醇 + 苯二氮䓬:0/0,0%;p = 1.00)存在任何统计学显著差异。
本研究发现,肌内注射或静脉注射奥氮平以及肌内注射或静脉注射氟哌利多或氟哌啶醇联合肌内注射或静脉注射苯二氮䓬后SBP下降。联合治疗后SBP的变化百分比和低血压发作频率在两组间无差异。联合治疗后两组在吸氧需求增加或因心肺抑制需要插管方面也无差异。本研究表明,在治疗成年急诊科患者的躁动时,肌内注射或静脉注射奥氮平联合肌内注射或静脉注射苯二氮䓬与肌内注射或静脉注射氟哌利多或氟哌啶醇联合肌内注射或静脉注射苯二氮䓬可能具有相当的心肺安全性。